Sun Andrew Y, Babbar Paurush, Gill Bradley C, Angermeier Kenneth W, Montague Drogo K
Cleveland Clinic, Glickman Urological and Kidney Institute, Cleveland, OH.
Cleveland Clinic, Glickman Urological and Kidney Institute, Cleveland, OH.
Urology. 2018 Jul;117:86-88. doi: 10.1016/j.urology.2018.03.048. Epub 2018 Apr 12.
To determine whether patients with solid organ transplant (SOT) are at higher risk of developing complications after inflatable penile prosthesis (IPP) implantation.
We retrospectively reviewed outcomes data for all patients with SOT who underwent IPP placement at our institution. A cohort of age-matched IPP recipients without SOT were used as controls.
We identified 26 patients who underwent SOT and IPP between 1999 and 2015, and 26 controls. Transplants included heart (3), liver (2), kidney only (17), and kidney and pancreas (4). Mean follow-up time after IPP placement was 29.5 months (SOT group) and 13.5 months (controls). Age at IPP did not significantly differ between groups (53.7 + 8.1 vs 56.4 + 9.0, P = .26), nor did body mass index (30.3 + 5.5 vs 30.2 + 4.7, P = .92), history of prostatectomy (7.7% vs 15.4%, P = .39), rectal surgery (3.9% vs 3.9%, P = 1.00), hyperlipidemia (69.2% vs 69.2%, P = 1.00), hypertension (92.3% vs 76.9%, P = .25), or heart disease (57.7% vs 30.8%, P = .093). Peripheral vascular disease was more common in transplant patients (26.9% vs 3.9%, P = .021), as were stroke (19.2% vs 0.0%, P = .05) and diabetes (84.6% vs 53.6%, P = .016). No significant differences in IPP reoperation rates existed between patients with vs without SOT (11.5% vs 11.5%, P = 1.00), nor did they differ by organ transplanted (P = 1.00). No differences in IPP reoperation rate existed between 2-piece vs 3-piece IPP models (P = .47).
Outcomes of IPP implantation in patients with SOT are similar to those of nontransplant patients. Patients with SOT should be considered suitable candidates for penile prosthesis.
确定实体器官移植（SOT）患者在植入可膨胀阴茎假体（IPP）后发生并发症的风险是否更高。
我们回顾性分析了在我们机构接受IPP植入的所有SOT患者的结局数据。将一组年龄匹配的未接受SOT的IPP接受者作为对照。
我们确定了1999年至2015年间26例接受SOT和IPP植入的患者以及26例对照。移植器官包括心脏（3例）、肝脏（2例）、单纯肾脏（17例）和肾脏及胰腺（4例）。IPP植入后的平均随访时间在SOT组为29.5个月，在对照组为13.5个月。两组患者IPP植入时的年龄无显著差异（53.7±8.1岁 vs 56.4±9.0岁，P = 0.26），体重指数也无显著差异（30.3±5.5 vs 30.2±4.7，P = 0.92），前列腺切除术史（7.7% vs 15.4%，P = 0.39）、直肠手术史（3.9% vs 3.9%，P = 1.00）、高脂血症（69.2% vs 69.2%，P = 1.00）、高血压（92.3% vs 76.9%，P = 0.25）或心脏病（57.7% vs 30.8%，P = 0.093）方面也无显著差异。外周血管疾病在移植患者中更常见（26.9% vs 3.9%，P = 0.021），中风（19.2% vs 0.0%，P = 0.05）和糖尿病（84.6% vs 53.6%，P = 0.016）也是如此。接受SOT和未接受SOT的患者在IPP再次手术率方面无显著差异（11.5% vs 11.5%，P = 1.00），按移植器官不同也无差异（P = 1.00）。两件式与三件式IPP模型在IPP再次手术率方面无差异（P = 0.47）。
SOT患者IPP植入的结局与非移植患者相似。SOT患者应被视为阴茎假体的合适候选者。
